Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Parasite DNA and other macromolecules represent a diverse group of essential biological targets within parasitic organisms, including protozoa and helminths [2, 4, 13]. This target category encompasses genomic and mitochondrial DNA, various RNA species, and functional proteins or lipids that are vital for the parasite's life cycle, replication, and metabolic processes [2, 4, 13]. Several antiparasitic drugs function as prodrugs that require metabolic activation by parasite-specific enzymes to form highly reactive intermediates [4, 14, 15]. These active metabolites then covalently bind to or alkylate DNA and other macromolecules, causing irreversible structural damage and disrupting critical functions such}
Drugs targeting parasite DNA and other macromolecules typically act through DNA alkylation, intercalation, or the formation of covalent adducts with essential proteins and nucleic acids [2, 4, 14]. Many of these agents are prodrugs activated by parasite-specific enzymes into reactive electrophiles or free radicals that cause irreversible damage to the parasite's genetic material and metabolic machinery [4, 12, 15].
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Parasite DNA and other macromolecules.